A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 784 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Working to Close the Cancer Screening Gap Caused by COVID May 17, 2022 Mom Battling Cancer Lets 4-Yr-Old Give Her “Best Haircut Ever.” December 6, 2019 Palliative and Supportive Care for Children With Cancer: An Expert Perspective October 5, 2023 4 Tips from Oncology Dietitians for Healthier Eating During Cancer January 2, 2024 Load more HOT NEWS Breast Cancer Survivor Comes First Woman In The World To Give... Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer Pyrotinib in HER2-mutated Advanced NSCLC Previously Treated with Chemotherapy EMA Recommends Extension of Therapeutic Indications for Selinexor
